Erasca doubles down on RAS
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
The conference’s abstract drop features ASC4First in its plenary session.
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
The $1bn price tag for the preclinical Mariana Oncology shows that competition for assets in this space is fierce.
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
Abstract titles reveal some of ASCO’s key datasets.
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.